Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey
Objective: The purpose of this study is to estimate the cost-effectiveness of screening, treatment, and examination of patients with type 2 diabetes during a yearly period and expose its importance in diabetes control. Materials and Methods: Five hundred patients with type 2 diabetes who had receive...
Gespeichert in:
| Veröffentlicht in: | İstanbul Tıp Fakültesi Dergisi 2017-09, Vol.80 (3), p.92-97 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 97 |
|---|---|
| container_issue | 3 |
| container_start_page | 92 |
| container_title | İstanbul Tıp Fakültesi Dergisi |
| container_volume | 80 |
| creator | YÜRÜYEN, Gülden ÖZGÜN ÇİL, Eylem ARMAN, Yücel DEMİR, Pınar ÇAKMAK, Ramazan AKCAN, Tuğçe ÖZCAN, Mustafa AKARSU, Murat ALTUN, Özgür AYDIN YOLDEMİR, Şengül KIRNA, Kerem TOPRAK, İlkim Deniz TÜKEK, Tufan |
| description | Objective: The purpose of this study is to estimate the cost-effectiveness of screening, treatment, and examination of patients
with type 2 diabetes during a yearly period and expose its importance in diabetes control.
Materials and Methods: Five hundred patients with type 2 diabetes who had received outpatient therapy in the past year
were enrolled in the study. Patients were divided into three categories according to their hemoglobin A1c (HbA1c) (%)
levels: good control (HbA1c 10%). Average annual costs
of treatment, examination, and laboratory workup were compared for the three groups.
Results: The average annual cost of medication for 500 type 2 diabetes patients was $556.50, while the cost of screening
and examination was $89.20 per patient. The average yearly treatment cost per patient was $287.90 for patients with HbA1c
≤7%, $647.90 for patients with HbA1c 7%–10%, and $752.40 patients with HbA1c ≥10%. The average annual costs of
treatment with only oral anti-diabetic drugs (OAD), insulin only, and both OAD and insulin were $154.80, $837.50, and
$819.30, respectively.
Conclusion: While the cost to treat diabetic patients with good control was significantly lower than the treatment cost of
patients with poor control, there was no significant difference in laboratory workup and examination costs. When patients
treated with OAD only, insulin only and OAD + insulin were compared, treatment costs for the OAD only group were
significantly lower than the costs to treat the insulin only and OAD + insulin groups. No correlation between age or sex
and medication cost were found. However, a strong correlation was found between diabetes duration and treatment cost. |
| doi_str_mv | 10.18017/iuitfd.363564 |
| format | Article |
| fullrecord | <record><control><sourceid>idealonline_cross</sourceid><recordid>TN_cdi_crossref_primary_10_18017_iuitfd_363564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IDEAL_64997</sourcerecordid><originalsourceid>FETCH-LOGICAL-c196t-a271aada9bc3e18f47d8546162c71d0b5a0464b33e14790b8282d82b6f6e44a33</originalsourceid><addsrcrecordid>eNotkD1PwzAYhD2ARFW6MntjSvFXnGSsSoFKESxltt7Er4VLSCLbQcq_pxCmk-5Op9NDyB1nW14yXjz4ySdnt1LLXKsrsuKS5ZlWUt6QTYxnxpjIOc-ZWpHX_RBThs5hm_w39hgjhR66OfpIB0fTPCIV1HpoMGGkvqfDlEZIHvtE0wcGGOdf9zSFT5xvybWDLuLmX9fk_elw2r9k9dvzcb-rs5ZXOmUgCg5goWpaibx0qrBlrjTXoi24ZU0OTGnVyEuoioo1pSiFLUWjnUalQMo1uV92vUXohr7zPZrzMIXL9WiOj4ddbbSqquLS3C7NNgwxBnRmDP4Lwmw4M3-4zILLLLjkD6xEYMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey</title><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>YÜRÜYEN, Gülden ; ÖZGÜN ÇİL, Eylem ; ARMAN, Yücel ; DEMİR, Pınar ; ÇAKMAK, Ramazan ; AKCAN, Tuğçe ; ÖZCAN, Mustafa ; AKARSU, Murat ; ALTUN, Özgür ; AYDIN YOLDEMİR, Şengül ; KIRNA, Kerem ; TOPRAK, İlkim Deniz ; TÜKEK, Tufan</creator><contributor>Öçal,Lale Mahdume</contributor><creatorcontrib>YÜRÜYEN, Gülden ; ÖZGÜN ÇİL, Eylem ; ARMAN, Yücel ; DEMİR, Pınar ; ÇAKMAK, Ramazan ; AKCAN, Tuğçe ; ÖZCAN, Mustafa ; AKARSU, Murat ; ALTUN, Özgür ; AYDIN YOLDEMİR, Şengül ; KIRNA, Kerem ; TOPRAK, İlkim Deniz ; TÜKEK, Tufan ; Öçal,Lale Mahdume</creatorcontrib><description>Objective: The purpose of this study is to estimate the cost-effectiveness of screening, treatment, and examination of patients
with type 2 diabetes during a yearly period and expose its importance in diabetes control.
Materials and Methods: Five hundred patients with type 2 diabetes who had received outpatient therapy in the past year
were enrolled in the study. Patients were divided into three categories according to their hemoglobin A1c (HbA1c) (%)
levels: good control (HbA1c <7%), fair control (HbA1c 7%–10%), and poor control (HbA1c >10%). Average annual costs
of treatment, examination, and laboratory workup were compared for the three groups.
Results: The average annual cost of medication for 500 type 2 diabetes patients was $556.50, while the cost of screening
and examination was $89.20 per patient. The average yearly treatment cost per patient was $287.90 for patients with HbA1c
≤7%, $647.90 for patients with HbA1c 7%–10%, and $752.40 patients with HbA1c ≥10%. The average annual costs of
treatment with only oral anti-diabetic drugs (OAD), insulin only, and both OAD and insulin were $154.80, $837.50, and
$819.30, respectively.
Conclusion: While the cost to treat diabetic patients with good control was significantly lower than the treatment cost of
patients with poor control, there was no significant difference in laboratory workup and examination costs. When patients
treated with OAD only, insulin only and OAD + insulin were compared, treatment costs for the OAD only group were
significantly lower than the costs to treat the insulin only and OAD + insulin groups. No correlation between age or sex
and medication cost were found. However, a strong correlation was found between diabetes duration and treatment cost.</description><identifier>ISSN: 1305-6433</identifier><identifier>ISSN: 1305-6441</identifier><identifier>DOI: 10.18017/iuitfd.363564</identifier><language>eng</language><publisher>İstanbul Üniversitesi Yayınları</publisher><subject>Tıp</subject><ispartof>İstanbul Tıp Fakültesi Dergisi, 2017-09, Vol.80 (3), p.92-97</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><contributor>Öçal,Lale Mahdume</contributor><creatorcontrib>YÜRÜYEN, Gülden</creatorcontrib><creatorcontrib>ÖZGÜN ÇİL, Eylem</creatorcontrib><creatorcontrib>ARMAN, Yücel</creatorcontrib><creatorcontrib>DEMİR, Pınar</creatorcontrib><creatorcontrib>ÇAKMAK, Ramazan</creatorcontrib><creatorcontrib>AKCAN, Tuğçe</creatorcontrib><creatorcontrib>ÖZCAN, Mustafa</creatorcontrib><creatorcontrib>AKARSU, Murat</creatorcontrib><creatorcontrib>ALTUN, Özgür</creatorcontrib><creatorcontrib>AYDIN YOLDEMİR, Şengül</creatorcontrib><creatorcontrib>KIRNA, Kerem</creatorcontrib><creatorcontrib>TOPRAK, İlkim Deniz</creatorcontrib><creatorcontrib>TÜKEK, Tufan</creatorcontrib><title>Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey</title><title>İstanbul Tıp Fakültesi Dergisi</title><description>Objective: The purpose of this study is to estimate the cost-effectiveness of screening, treatment, and examination of patients
with type 2 diabetes during a yearly period and expose its importance in diabetes control.
Materials and Methods: Five hundred patients with type 2 diabetes who had received outpatient therapy in the past year
were enrolled in the study. Patients were divided into three categories according to their hemoglobin A1c (HbA1c) (%)
levels: good control (HbA1c <7%), fair control (HbA1c 7%–10%), and poor control (HbA1c >10%). Average annual costs
of treatment, examination, and laboratory workup were compared for the three groups.
Results: The average annual cost of medication for 500 type 2 diabetes patients was $556.50, while the cost of screening
and examination was $89.20 per patient. The average yearly treatment cost per patient was $287.90 for patients with HbA1c
≤7%, $647.90 for patients with HbA1c 7%–10%, and $752.40 patients with HbA1c ≥10%. The average annual costs of
treatment with only oral anti-diabetic drugs (OAD), insulin only, and both OAD and insulin were $154.80, $837.50, and
$819.30, respectively.
Conclusion: While the cost to treat diabetic patients with good control was significantly lower than the treatment cost of
patients with poor control, there was no significant difference in laboratory workup and examination costs. When patients
treated with OAD only, insulin only and OAD + insulin were compared, treatment costs for the OAD only group were
significantly lower than the costs to treat the insulin only and OAD + insulin groups. No correlation between age or sex
and medication cost were found. However, a strong correlation was found between diabetes duration and treatment cost.</description><subject>Tıp</subject><issn>1305-6433</issn><issn>1305-6441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNotkD1PwzAYhD2ARFW6MntjSvFXnGSsSoFKESxltt7Er4VLSCLbQcq_pxCmk-5Op9NDyB1nW14yXjz4ySdnt1LLXKsrsuKS5ZlWUt6QTYxnxpjIOc-ZWpHX_RBThs5hm_w39hgjhR66OfpIB0fTPCIV1HpoMGGkvqfDlEZIHvtE0wcGGOdf9zSFT5xvybWDLuLmX9fk_elw2r9k9dvzcb-rs5ZXOmUgCg5goWpaibx0qrBlrjTXoi24ZU0OTGnVyEuoioo1pSiFLUWjnUalQMo1uV92vUXohr7zPZrzMIXL9WiOj4ddbbSqquLS3C7NNgwxBnRmDP4Lwmw4M3-4zILLLLjkD6xEYMw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>YÜRÜYEN, Gülden</creator><creator>ÖZGÜN ÇİL, Eylem</creator><creator>ARMAN, Yücel</creator><creator>DEMİR, Pınar</creator><creator>ÇAKMAK, Ramazan</creator><creator>AKCAN, Tuğçe</creator><creator>ÖZCAN, Mustafa</creator><creator>AKARSU, Murat</creator><creator>ALTUN, Özgür</creator><creator>AYDIN YOLDEMİR, Şengül</creator><creator>KIRNA, Kerem</creator><creator>TOPRAK, İlkim Deniz</creator><creator>TÜKEK, Tufan</creator><general>İstanbul Üniversitesi Yayınları</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope></search><sort><creationdate>20170901</creationdate><title>Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey</title><author>YÜRÜYEN, Gülden ; ÖZGÜN ÇİL, Eylem ; ARMAN, Yücel ; DEMİR, Pınar ; ÇAKMAK, Ramazan ; AKCAN, Tuğçe ; ÖZCAN, Mustafa ; AKARSU, Murat ; ALTUN, Özgür ; AYDIN YOLDEMİR, Şengül ; KIRNA, Kerem ; TOPRAK, İlkim Deniz ; TÜKEK, Tufan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c196t-a271aada9bc3e18f47d8546162c71d0b5a0464b33e14790b8282d82b6f6e44a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Tıp</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YÜRÜYEN, Gülden</creatorcontrib><creatorcontrib>ÖZGÜN ÇİL, Eylem</creatorcontrib><creatorcontrib>ARMAN, Yücel</creatorcontrib><creatorcontrib>DEMİR, Pınar</creatorcontrib><creatorcontrib>ÇAKMAK, Ramazan</creatorcontrib><creatorcontrib>AKCAN, Tuğçe</creatorcontrib><creatorcontrib>ÖZCAN, Mustafa</creatorcontrib><creatorcontrib>AKARSU, Murat</creatorcontrib><creatorcontrib>ALTUN, Özgür</creatorcontrib><creatorcontrib>AYDIN YOLDEMİR, Şengül</creatorcontrib><creatorcontrib>KIRNA, Kerem</creatorcontrib><creatorcontrib>TOPRAK, İlkim Deniz</creatorcontrib><creatorcontrib>TÜKEK, Tufan</creatorcontrib><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><jtitle>İstanbul Tıp Fakültesi Dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YÜRÜYEN, Gülden</au><au>ÖZGÜN ÇİL, Eylem</au><au>ARMAN, Yücel</au><au>DEMİR, Pınar</au><au>ÇAKMAK, Ramazan</au><au>AKCAN, Tuğçe</au><au>ÖZCAN, Mustafa</au><au>AKARSU, Murat</au><au>ALTUN, Özgür</au><au>AYDIN YOLDEMİR, Şengül</au><au>KIRNA, Kerem</au><au>TOPRAK, İlkim Deniz</au><au>TÜKEK, Tufan</au><au>Öçal,Lale Mahdume</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey</atitle><jtitle>İstanbul Tıp Fakültesi Dergisi</jtitle><date>2017-09-01</date><risdate>2017</risdate><volume>80</volume><issue>3</issue><spage>92</spage><epage>97</epage><pages>92-97</pages><issn>1305-6433</issn><issn>1305-6441</issn><abstract>Objective: The purpose of this study is to estimate the cost-effectiveness of screening, treatment, and examination of patients
with type 2 diabetes during a yearly period and expose its importance in diabetes control.
Materials and Methods: Five hundred patients with type 2 diabetes who had received outpatient therapy in the past year
were enrolled in the study. Patients were divided into three categories according to their hemoglobin A1c (HbA1c) (%)
levels: good control (HbA1c <7%), fair control (HbA1c 7%–10%), and poor control (HbA1c >10%). Average annual costs
of treatment, examination, and laboratory workup were compared for the three groups.
Results: The average annual cost of medication for 500 type 2 diabetes patients was $556.50, while the cost of screening
and examination was $89.20 per patient. The average yearly treatment cost per patient was $287.90 for patients with HbA1c
≤7%, $647.90 for patients with HbA1c 7%–10%, and $752.40 patients with HbA1c ≥10%. The average annual costs of
treatment with only oral anti-diabetic drugs (OAD), insulin only, and both OAD and insulin were $154.80, $837.50, and
$819.30, respectively.
Conclusion: While the cost to treat diabetic patients with good control was significantly lower than the treatment cost of
patients with poor control, there was no significant difference in laboratory workup and examination costs. When patients
treated with OAD only, insulin only and OAD + insulin were compared, treatment costs for the OAD only group were
significantly lower than the costs to treat the insulin only and OAD + insulin groups. No correlation between age or sex
and medication cost were found. However, a strong correlation was found between diabetes duration and treatment cost.</abstract><pub>İstanbul Üniversitesi Yayınları</pub><doi>10.18017/iuitfd.363564</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1305-6433 |
| ispartof | İstanbul Tıp Fakültesi Dergisi, 2017-09, Vol.80 (3), p.92-97 |
| issn | 1305-6433 1305-6441 |
| language | eng |
| recordid | cdi_crossref_primary_10_18017_iuitfd_363564 |
| source | DOAJ Directory of Open Access Journals; Alma/SFX Local Collection |
| subjects | Tıp |
| title | Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-idealonline_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20analysis%20of%20type%202%20diabetes%20in%20outpatient%20therapy%20in%20Turkey&rft.jtitle=%C4%B0stanbul%20T%C4%B1p%20Fak%C3%BCltesi%20Dergisi&rft.au=Y%C3%9CR%C3%9CYEN,%20G%C3%BClden&rft.date=2017-09-01&rft.volume=80&rft.issue=3&rft.spage=92&rft.epage=97&rft.pages=92-97&rft.issn=1305-6433&rft_id=info:doi/10.18017/iuitfd.363564&rft_dat=%3Cidealonline_cross%3EIDEAL_64997%3C/idealonline_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |